Your browser is no longer supported. Please, upgrade your browser.
Aridis Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-2.48 Insider Own37.03% Shs Outstand8.92M Perf Week11.62%
Market Cap70.39M Forward P/E- EPS next Y-3.47 Insider Trans0.00% Shs Float6.34M Perf Month0.14%
Income-22.20M PEG- EPS next Q-0.59 Inst Own1.80% Short Float0.08% Perf Quarter-7.79%
Sales1.00M P/S70.39 EPS this Y-21.30% Inst Trans- Short Ratio0.35 Perf Half Y-3.33%
Book/sh-1.27 P/B- EPS next Y-42.20% ROA-110.50% Target Price- Perf Year-0.28%
Cash/sh0.63 P/C11.35 EPS next 5Y- ROE550.10% 52W Range3.80 - 10.18 Perf YTD17.13%
Dividend- P/FCF- EPS past 5Y- ROI-808.00% 52W High-30.16% Beta-
Dividend %- Quick Ratio0.60 Sales past 5Y- Gross Margin- 52W Low87.11% ATR0.41
Employees25 Current Ratio0.60 Sales Q/Q- Oper. Margin- RSI (14)60.72 Volatility6.11% 6.07%
OptionableNo Debt/Eq- EPS Q/Q25.70% Profit Margin- Rel Volume0.36 Prev Close7.10
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume14.25K Price7.11
Recom2.00 SMA2010.14% SMA505.95% SMA2002.67% Volume5,090 Change0.14%
Feb-19-20Initiated ROTH Capital Buy $18
Nov-24-20 05:30AM  
Nov-20-20 04:05PM  
Oct-27-20 04:24PM  
Oct-19-20 08:30AM  
Oct-14-20 05:30AM  
Sep-08-20 05:30AM  
Sep-04-20 01:32PM  
Aug-11-20 04:05PM  
Jul-15-20 08:42AM  
Jun-26-20 05:30AM  
Jun-22-20 05:30AM  
Jun-18-20 05:30AM  
Jun-15-20 05:30AM  
May-12-20 04:05PM  
May-07-20 12:08PM  
May-04-20 05:30AM  
Apr-29-20 05:30AM  
Apr-15-20 02:28PM  
Apr-08-20 04:59PM  
Mar-06-20 04:05PM  
Mar-05-20 05:30AM  
Mar-04-20 05:30AM  
Feb-28-20 02:15PM  
Feb-18-20 05:30AM  
Jan-28-20 02:56PM  
Jan-17-20 05:34AM  
Jan-03-20 02:44PM  
Jan-02-20 08:46AM  
Nov-13-19 04:05PM  
Oct-19-19 08:47AM  
Oct-11-19 05:30AM  
Sep-30-19 05:30AM  
Sep-27-19 05:45AM  
Sep-08-19 04:28PM  
Sep-03-19 09:18AM  
Aug-14-19 03:40PM  
Aug-12-19 04:05PM  
Jul-31-19 03:01PM  
Jul-30-19 05:30AM  
Jul-19-19 05:30AM  
Jun-27-19 05:30AM  
Jun-10-19 05:30AM  
May-14-19 04:35PM  
Apr-03-19 07:21AM  
Apr-02-19 09:00AM  
Mar-28-19 04:05PM  
Jan-31-19 10:40AM  
Jan-02-19 01:15PM  
Dec-12-18 07:30AM  
Dec-05-18 10:35AM  
Dec-04-18 12:30PM  
Nov-26-18 10:04AM  
Nov-21-18 07:35AM  
Nov-13-18 07:30AM  
Nov-07-18 07:30AM  
Sep-26-18 08:30AM  
Sep-24-18 07:00AM  
Aug-13-18 07:31PM  
Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-105, a fully human IgG1 mAb, which is in Phase II trials to target gram-negative bacteria P. aeruginosa; AR-101, a human IgM mAb, which is in Phase II clinical trials for the treatment of hospital-acquired pneumonia (HAP)and ventilator-associated pneumonia (VAP) caused by P. aeruginosa serotype O11; AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-501, an anti-infective therapy, which is in Phase I/IIa clinical trial to manage chronic lung infections in cystic fibrosis patients and acute pneumonia in HAP and VAP patients. Aridis Pharmaceuticals, Inc. was founded in 2003 and is headquartered in San Jose, California.